Jan. 29, 2025 — Study finds three new safe and effective drug regimens to fight multidrug-resistant TB. The treatments, which include recently discovered TB drugs, give new options for shorter ...
Morgan Stanley analyst Roy Campbell maintained a Buy rating on Karooooo (KARO – Research Report) today and set a price target of $43.00. The company’s shares closed yesterday at $45.49.
Piramal Pharma launched Chlorpromazine Hydrochloride in the US last week. The company reported a 14% growth in its complex hospital generics business, led by strong sales in inhalation anaesthesia ...
LabVantage Pharma is the only pre-configured and pre-validated pharmaceutical LIMS in the world. This greatly lowers the deployment cost (85%) and time (75%) compared to a traditional LIMS ...
In a report released today, Roy Campbell from Morgan Stanley maintained a Buy rating on Karooooo (KARO – Research Report), with a price target of $43.00. The company’s shares closed last ...